论文部分内容阅读
目的探讨依达拉奉治疗急性脑梗死的临床疗效。方法选取2012年2月—2014年2月诊断并收治的急性脑梗死患者300例,根据患者就诊时间分为观察组和对照组,各150例。对照组进行抗凝、控制血压、补液等常规治疗,观察组在常规治疗基础上使用依达拉奉治疗,连续治疗14d,观察比较两组治疗后临床疗效及不良反应。结果观察组总有效率高于对照组(χ2=13.27,P<0.01),观察组神经功能(CSS)评分高于对照组(t=2.31,P<0.05),两组不良反应发生率比较,差异无统计学意义(χ2=0.09,P>0.05)。结论依达拉奉治疗急性脑梗死的临床疗效显著,可显著改善神经功能,安全性较高。
Objective To investigate the clinical efficacy of edaravone in the treatment of acute cerebral infarction. Methods 300 patients with acute cerebral infarction who were diagnosed and treated from February 2012 to February 2014 were divided into observation group and control group according to the time of visiting the patients, each of 150 cases. The control group was given conventional anticoagulation, blood pressure control and fluid replacement. The observation group was treated with edaravone on the basis of routine treatment for 14 days. The clinical effects and adverse reactions of the two groups were observed and compared. Results The total effective rate of the observation group was higher than that of the control group (χ2 = 13.27, P <0.01). The CSS score of the observation group was higher than that of the control group (t = 2.31, P <0.05) The difference was not statistically significant (χ2 = 0.09, P> 0.05). Conclusion Edaravone has a significant clinical effect in treating acute cerebral infarction, which can significantly improve neurological function and have higher safety.